Oncotelic Therapeutics Featured in Editorial Highlighting Intranasal Drug Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics' intranasal nose-to-brain delivery platform, featured in a BioMedWire editorial, addresses key challenges in CNS drug delivery for Alzheimer's disease and biodefense research by bypassing the blood-brain barrier.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies addressing challenges in Alzheimer’s disease and biodefense research. The editorial highlights the company’s proprietary intranasal nose-to-brain delivery platform, designed to bypass the blood-brain barrier and enable direct therapeutic delivery to the central nervous system, reflecting growing interest in advanced drug delivery approaches for neurological treatment.
The blood-brain barrier has long been a major obstacle in treating central nervous system disorders, preventing many potential therapies from reaching their targets. Oncotelic's platform offers a non-invasive alternative that could significantly improve drug efficacy for conditions like Alzheimer's disease, which affects millions worldwide. Additionally, the technology has implications for biodefense, potentially enabling rapid delivery of countermeasures against biological threats that target the CNS.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens Oncotelic’s position in oncology and rare disease therapeutics.
The editorial, published by BioMedWire, is part of a broader effort to highlight innovative approaches in the biotech and life sciences sectors. BioMedWire is a specialized communications platform within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions, article syndication to 5,000+ outlets, and social media distribution. For more information, visit BioMedWire.com. The full press release is available at https://ibn.fm/aSsCf.